Tenax Therapeutics, Inc. (NASDAQ:TENX) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07
Stockholders on June 14, 2017 (the Annual Meeting). The
stockholders considered the three proposals described below, each
of which is described in more detail in the Companys definitive
proxy statement dated April 28, 2017. As of April 17, 2017, the
record date for the Annual Meeting, there were 28,236,494 shares
of common stock issued, outstanding and entitled to vote. At the
Annual Meeting, 16,560,547 shares of common stock were
represented in person or by proxy, constituting a quorum. The
final number of votes cast for and against, as well as the number
of abstentions and broker non-votes, with respect to each
proposal are set forth below.
Board of Directors to serve until the sooner of the election and
qualification of their successors or the next Annual Meeting of
the Companys Stockholders. The votes were cast as follows:
|
For
|
Withheld
|
Broker Non-Votes
|
|
|
Ronald R. Blanck, DO
|
3,172,855
|
1,084,530
|
12,303,162
|
|
Anthony A. DiTonno
|
4,139,418
|
117,967
|
12,303, 162
|
|
James Mitchum
|
4,140,091
|
117,294
|
12,303, 162
|
|
Gregory Pepin
|
3,164,633
|
1,082,752
|
12,303, 162
|
|
Gerald T. Proehl
|
4,140,060
|
117,325
|
12,303, 162
|
|
Chris A. Rallis
|
4,140,974
|
116,411
|
12,303, 162
|
the Companys independent registered public accounting firm for
the fiscal year ending December 31, 2017. The votes were cast as
follows:
|
For
|
Against
|
Abstain
|
||
|
15,091,123
|
721,271
|
748,153
|
Officer compensation. The votes were cast as follows:
|
For
|
Against
|
Abstain
|
Broker Non-Votes
|
|||
|
3,958,457
|
232,710
|
66,218
|
12,303, 162
|
About Tenax Therapeutics, Inc. (NASDAQ:TENX)
Tenax Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing products for the critical care market. The Company’s main product is levosimendan. Levosimendan is a calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure. Levosimendan represents therapeutic modalities for the treatment of Low Cardiac Output Syndrome (LCOS), septic shock and other critical care conditions. The therapeutic effects of levosimendan are mediated through increased cardiac contractility by calcium sensitization of troponin C, resulting in a positive inotropic effect, which is not associated with substantial increases in oxygen demand; opening of potassium channels in the vasculature smooth muscle, resulting in a vasodilatory effect on all vascular beds, and opening of mitochondrial potassium channels in cardiomyocytes, resulting in a cardioprotective effect.
